Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Controlled Trial Evaluating the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

NCT06224660 is registered in ClinicalTrials.gov with Sardocor Corp. as lead sponsor.

NCT NCT06224660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Controlled Trial Evaluating the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
Lead sponsor
Sardocor Corp.
Phase
Phase 1
Overall status
Recruiting
Start date
October 2, 2024
Completion date
October 31, 2030
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dmd-associated dilated cardiomyopathy